Kinaset Therapeutics is a biopharmaceutical company focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. The Company’s lead clinical candidate, KN-002, is a novel and non-invasive anti-inflammatory being developed to treat all patients with severe asthma regardless of the underlying cause of inflammation. Formulated as a dry powder that is inhalable for ease of use, KN-002 has enhanced targeted delivery directly to the site of inflammation in the lungs with reduced systemic exposure, which could provide a safer and more effective treatment option for patients. Kinaset is advancing the inhaled small molecule as a potential treatment for additional respiratory indications, including chronic obstructive pulmonary disease (COPD) and sees potential for indications outside of respiratory disease, such as dermatology. Backed by founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company.